Treatment for rheumatoid arthritis with immunogene therapy by angiostatin

点击翻译按钮获取中文摘要

The aim of this research is establishment of antigen-specific immunogene therapy for rheumatoid arthritis with angiostatin. At first, we combined IL-10 expression vector and monoclonal antibodies against human ICAM-1 using sulfo-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC). Then we added the conjugates to ICAM-1 expressing cells (ICAM-1 COS ; COS cells stably trasfected with ICAM-1 expression vector, synovial fibroblast cell line E11). We detected significant IL-10 in the supernatant of ICAM-1 expressing cells but not in control COS cells after 72hour incubation with immunogene. The tranfection efficiency increased four times when the expression vector was conjugated to Fab fragment of antibody. The addition of native antibody to the medium reduced transfection efficiency, supporting antigen-specific gene delivery of this method. We are planning to conjugate angiostatin gene and ICAM-1 monoclonal antibody and infuse to RA SCID mice (SCID mice transplanted with human synovial tissue)